Survival of COVID-19 Patients Who Received Antiviral and Antiviral Therapy Combined with Anti-inflammation Therapy in a National Referral Hospital, Indonesia

Abstract

Background: COVID-19 has infected and spread over the whole earth. For the time being, there is no cure for COVID 19. Although several medications have the potential to be utilized at various stages of the disease, no therapy has yet been demonstrated to be completely successful.
 Aim: This study aims to determine survival of COVID-19 patients who received antiviral and antiviral therapy combined with anti-inflammation therapy in a national referral hospital Indonesia.
 Methods: COVID-19 patients treated at Dr. M Djamil General Hospital in Padang, Indonesia were the subject of an analytic investigation using a retrospective cohort design. From January to June 2021, data was gathered from patient medical records. Independent sample T test and Chi-square test were used to analyze subject characteristics data. The median survival and survival rates were calculated using Kaplan-Meier survival analysis. It is also subjected to cox-regression analysis in order to answer the study hypothesis.
 Results: The mean age of the subjects who received antiviral and anti-inflammatory medication was 60.95 12.11 years, while the average age of those who received antiviral therapy was 56.72 17.80 years, with the highest sex being male in both groups (59.3 percent ; 50.6 percent ). Antiviral and antiviral medication, as well as anti-inflammatory therapy, had no effect on the length of stay of COVID-19 patients (p>0.05). Antiviral and antiviral therapy, as well as anti-inflammatory therapy, play a role in the outcome of COVID-19 patients (p<0.05), with patients receiving antiviral and anti-inflammatory therapy being a preventive factor in the final outcome of patients compared to patients receiving antiviral therapy HR = 0.69 (95% CI 0.48-0.99).
 Conclusion: When compared to patients who just got antiviral medication, patients who received antiviral plus anti-inflammatory therapy had a better outcome.

The THE ROLE OF AGE AND COMORBIDITIES ON THE OUTCOME OF CONFIRMED CLINICALLY CRITICAL COVID-19 PATIENTS TREATED WITH REMDESIVIR AT INDONESIA'S NATIONAL REFERRAL HOSPITAL

“…Patients with a history of respiratory disease, such as COPD, have lower viral resistance and are more likely to develop acute respiratory distress syndrome (ARDS) (Saguil et al, 2020). Diabetes, hypertension, cardiovascular disease, and respiratory disease are all risk factors for disease development (Zheng et al, 2020;Afriani et al, 2022). This study's main strength was being the first study to the role of age and comorbidities on the outcome of confirmed clinically critical COVID-19 patients treated with remdesivir at one of Indonesia's national referral hospitals.…”